Home/Pipeline/INM-088

INM-088

Glaucoma

PreclinicalActive

Key Facts

Indication

Glaucoma

Phase

Preclinical

Status

Active

Company

InMed Pharmaceuticals

About InMed Pharmaceuticals

InMed Pharmaceuticals is executing a dual-pillar strategy to de-risk its business model: developing proprietary cannabinoid-based drug candidates for diseases with high unmet need and manufacturing rare cannabinoids for commercial and research use. Its core differentiator is the IntegraSyn™ biosynthesis platform, which enables scalable, consistent production of cannabinoids difficult to source from plants. Key achievements include advancing its lead candidate, INM-755, into clinical trials for epidermolysis bullosa and establishing its capabilities as a potential supplier in the rare cannabinoid market. The company's mission is to apply rigorous pharmaceutical development to cannabinoids, transforming them into defined, reproducible medicines.

View full company profile

Therapeutic Areas

Dermatology Ophthalmology

Other Glaucoma Drugs

Drug	Company	Phase	Status
PREZIA Glaucoma Implant	PolyActiva	Preclinical	Active
MIGS Device System	Micropoint Biotechnologies	Commercial	Market approved in China
OT-401	Ocumension Therapeutics	Phase 2	Active
ANX007	Annexon Biosciences	Phase 2	Active
PER-001	Perfuse Therapeutics	Phase 2	Active
hOTX2	BrainEver	Discovery	Active
Glaucoma Treatment	BVI Medical	Commercial	Active
MediPrint Lens (Glaucoma)	MediPrint Ophthalmics	Phase 2b	Active
Glaucoma Program	Broadwing Bio	Pre-clinical	Active
MSC Exosomal Eye Serum	Vitti Labs	Pre-clinical	Active
BTQ1902	Betaliq	Phase 2	Active
TODDD™ Platform	Amorphex Therapeutics	Pre-clinical	Active